Brief: Nls Pharmaceutics AG Exclusive Option Agreement To Develop And Commercialize Next Generation Dual Orexin Agonist Platform Of Aexon Labs, Inc

NewcelX AG

01/12/2023 15:35

Dec 1 (Reuters) - NLS Pharmaceutics AG  NLSP.O :
    * NLS PHARMACEUTICS AG: EXCLUSIVE OPTION AGREEMENT TO
DEVELOP AND
COMMERCIALIZE NEXT GENERATION DUAL OREXIN AGONIST PLATFORM OF
AEXON LABS, INC
    * NLS PHARMACEUTICS AG: UNDER TERMS OF OPTION AGREEMENT, NLS
MUST
EXERCISE ITS OPTION BY NO LATER THAN MARCH 31, 2024
    * NLS PHARMACEUTICS AG: AEXON LABS TO INITIATE CLINICAL
DEVELOPMENT, INCLUDING PHASE 1 FIRST-IN-HUMAN, PHASE 1B
PROOF-OF-CONCEPT STUDIES, EARLY AS 2024

Further company coverage:  NLSP.O 

 ((Reuters.Briefs@thomsonreuters.com;))